Politico August 13, 2024
INNOVATORS
Don’t count out magic mushrooms.
That’s the message from British biotech company Compass Pathways, which is evaluating ‘shrooms, or psilocybin, alongside psychological support, for treatment-resistant depression.
Approval of the regimen by the FDA could render the agency’s decision last week to reject a different treatment protocol for post-traumatic stress disorder involving the drug MDMA a mere setback in the psychedelic revolution.
The FDA’s decision on MDMA isn’t affecting Compass’ Phase 3 trials, according to Chris Williams, Compass’ chief communications officer.
“Robust monitoring and rigorous standards are at the core of our programs at Compass and we believe that generating clear and compelling clinical evidence is the best way to bring new medicines to patients as quickly as possible,” Williams...
Today's Sponsors
Today's Sponsor